It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The MARCH E3 ubiquitin (Ub) ligase MARCH1 regulates trafficking of major histocompatibility complex class II (MHC II) and CD86, molecules of critical importance to immunity. Here we show, using a genome-wide CRISPR knockout screen, that ubiquitin-like protein 3 (UBL3) is a necessary component of ubiquitination-mediated trafficking of these molecules in mice and in humans. Ubl3-deficient mice have elevated MHC II and CD86 expression on the surface of professional and atypical antigen presenting cells. UBL3 also regulates MHC II and CD86 in human dendritic cells (DCs) and macrophages. UBL3 impacts ubiquitination of MARCH1 substrates, a mechanism that requires UBL3 plasma membrane anchoring via prenylation. Loss of UBL3 alters adaptive immunity with impaired development of thymic regulatory T cells, loss of conventional type 1 DCs, increased number of trogocytic marginal zone B cells, and defective in vivo MHC II and MHC I antigen presentation. In summary, we identify UBL3 as a conserved, critical factor in MARCH1-mediated ubiquitination with important roles in immune responses.
Regulated trafficking of major histocompatibility complex class II and CD86 is a prerequisite of antigen presenting cell functionality. Authors show here that ubiquitin-like protein 3 is critically involved in the ubiquitination process that controls trafficking, with wide-ranging immunological consequences.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details














1 The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Pharmacology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
2 PSL Research University, INSERM, U932, Institut Curie, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389)
3 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889)
4 La Trobe University, Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, Bundoora, Australia (GRID:grid.1018.8) (ISNI:0000 0001 2342 0938)
5 The University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
6 The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Pharmacology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
7 The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Pharmacology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); New York University College of Dentistry, Department of Oral and Maxillofacial Surgery, Bluestone Center for Clinical Research, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); Monash University, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
8 Monash University, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
9 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)